Genome-wide screening for understanding the role of DNA methylation in colorectal cancer

Epigenomics

Volumn 5, Issue 5, 2013, Pages 569-581

  Sipos, Ferenc ^a   Mũzes, Györgyi ^a   Patai, Árpád V ^a   Fũri, István ^a   Péterfia, Bálint ^a   Hollósi, Péter ^a   Molnár, Béla ^a,b   Tulassay, Zsolt ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

bisulfite treatment; colorectal cancer; epigenetics; genome wide DNA methylation; next generation sequencing

Indexed keywords

BISULFITE; CURCUMIN; DNA; GENOMIC DNA; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 2; METHYL CPG BINDING PROTEIN 3; RESTRICTION ENDONUCLEASE; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER SCREENING; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; COLITIS; COLORECTAL CANCER; COMPARATIVE STUDY; CPG ISLAND; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA DEGRADATION; DNA DENATURATION; DNA METHYLATION; DNA MICROARRAY; DNA REPAIR; ENTERITIS; EPIGENETICS; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOPRECIPITATION; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; COLORECTAL TUMOR; GENETICS;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENOMICS; HUMANS;

EID: 84885008597     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.13.52     Document Type: Review

References (106)

1. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007).
2. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat. Rev. Genet. 11(3), 191-203 (2010).
3. Laird PW. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3(4), 253-266 (2003).
4. Schones DE, Zhao K. Genome-wide approaches to studying chromatin modifications. Nat. Rev. Genet. 9(3), 179-191 (2008).
5. Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques 33(3), 632-649 (2002).
6. Pomraning KR, Smith KM, Freitag M. Genome-wide high throughput analysis of DNA methylation in eukaryotes. Methods 47(3), 142-150 (2009).
7. Fouse SD, Nagarajan RO, Costello JF. Genome-scale DNA methylation analysis. Epigenomics 2(1), 105-117 (2010).
8. Huang YW, Huang TH, Wang LS. Profiling DNA methylomes from microarray to genome-scale sequencing. Technol. Cancer Res. Treat. 9(2), 139-147 (2010).
9. Estecio MR, Yan PS, Ibrahim AE et al. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res. 17(10), 1529-1536 (2007).
10. Weber M, Davies JJ, Wittig D et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 37(8), 853-862 (2005).
11. Taiwo O, Wilson GA, Morris T et al. Methylome analysis using MeDIP-seq with low DNA concentrations. Nat. Protoc. 7(4), 617-636 (2012).
12. Jacinto FV, Ballestar E, Esteller M. Methyl- DNA immunoprecipitation (MeDIP): hunting down the DNA methylome. Biotechniques 44(1), 35, 37, 39 passim (2008).
13. Meehan RR, Lewis JD, Bird AP. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20(19), 5085-5092 (1992).
14. Down TA, Rakyan VK, Turner DJ et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat. Biotechnol. 26(7), 779-785 (2008).
15. Rauch T, Li H, Wu X, Pfeifer GP. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res. 66(16), 7939-7947 (2006).
16. Serre D, Lee BH, Ting AH. MBD-isolated genome sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res. 38(2), 391-399 (2010).
17. De Meyer T, Mampaey E, Vlemmix M et al. Quality evaluation of methyl binding domain based kits for enrichment DNA-methylation sequencing. PLoS One 8(3), e59068 (2013).
18. Brinkman AB, Simmer F, Ma K, Kaan A, Zhu J, Stunnenberg HG. Whole-genome DNA methylation profiling using MethylCap-seq. Methods 52(3), 232-236 (2010).
19. Simmer F, Brinkman AB, Assenov Y et al. Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics 7(12), 1355-1367 (2012).
20. Touleimat N, Tost J. Complete pipeline for Infinium® human methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation. Epigenomics 4(3), 325-341 (2012).
21. Bibikova M, Lin Z, Zhou L et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 16(3), 383-393 (2006).
22. Jasmine F, Rahaman R, Roy S et al. Interpretation of genome-wide infinium methylation data from ligated DNA in formalin-fixed, paraffin-embedded paired tumor and normal tissue. BMC Res. Notes 5, 117 (2012).
23. Bibikova M, Le J, Barnes B et al. Genome-wide DNA methylation profiling using Infinium assay. Epigenomics 1(1), 177-200 (2009).
24. Meissner A, Gnirke A, Bell GW, Ramsahoye B, Lander ES, Jaenisch R. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 33(18), 5868-5877 (2005).
25. Gu H, Smith ZD, Bock C, Boyle P, Gnirke A, Meissner A. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat. Protoc. 6(4), 468-481 (2011).
26. Schillebeeckx M, Schrade A, Löbs AK, Pihlajoki M, Wilson DB, Mitra RD. Laser capture microdissection-reduced representation bisulfite sequencing (LCM-RRBS) maps changes in DNA methylation associated with gonadectomy-induced adrenocortical neoplasia in the mouse. Nucleic Acids. Res. 41(11), 116 (2013).
27. Boyle P, Clement K, Gu H et al. Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling. Genome Biol. 13(10), R92 (2012).
28. Oda M, Glass JL, Thompson RF et al. High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res. 37(12), 3829-3839 (2009).
29. Bock C, Tomazou EM, Brinkman AB et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat. Biotechnol. 28(10), 1106-1114 (2010).
30. Li N, Ye M, Li Y et al. Whole genome DNA methylation analysis based on high throughput sequencing technology. Methods 52(3), 203-212 (2010).
31. Nair SS, Coolen MW, Stirzaker C et al. Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl- CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias. Epigenetics 6(1), 34-44 (2011).
32. Clark C, Palta P, Joyce CJ et al. A comparison of the whole genome approach of MeDIP-seq to the targeted approach of the infinium human methylation450 BeadChip® for methylome profiling. PLoS One 7(11), e50233 (2012).
33. Pedersen IS, Krarup HB, Thorlacius-Ussing O, Madsen PH. High recovery of cell-free methylated DNA based on a rapid bisulfite-treatment protocol. BMC Mol. Biol. 13, 12 (2012).
34. Yokoyama S, Kitamoto S, Yamada N et al. The application of methylation specific electrophoresis (MSE) to DNA methylation analysis of the 5́ CpG island of mucin in cancer cells. BMC Cancer 12, 67 (2012).
35. Tierling S, Schuster M, Tetzner R, Walter J. A combined HM-PCR/SNuPE method for high sensitive detection of rare DNA methylation. Epigenetics Chromatin 3(1), 12 (2010).
36. Kneip C, Schmidt B, Fleischhacker M et al. A novel method for sensitive and specific detection of DNA methylation biomarkers based on DNA restriction during PCR cycling. Biotechniques 47(3), 737-744 (2009).
37. Bock C, Lengauer T. Computational epigenetics. Bioinformatics 24(1), 1-10 (2008).
38. Lister R, Pelizzola M, Dowen RH et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009).
39. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765- 781 (2010).
40. Remo A, Pancione M, Zanella C, Vendraminelli R. Molecular pathology of colorectal carcinoma. A systematic review centred on the new role of the pathologist. Pathologica 104(6), 432-441 (2012).
41. Di Lena M, Travaglio E, Altomare DF. New strategies for colorectal cancer screening. World J. Gastroenterol. 19(12), 1855-1860 (2013).
42. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683-692 (2007).
43. Wong NC, Craig JM. Epigenetics: A Reference Manual. Caister Academic Press, Norfolk, England (2011).
44. Cadieux B, Ching TT, VandenBerg SR, Costello JF. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res. 66(17), 8469-8476 (2006).
45. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96(15), 8681-8686 (1999).
46. Fernandez-Rozadilla C, Cazier JB, Tomlinson IP et al. A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12. BMC Genomics 14, 55 (2013).
47. Jiao S, Hsu L, Berndt S et al. Genome-wide search for gene-gene interactions in colorectal cancer. PLoS One 7(12), e52535 (2012).
48. Jia WH, Zhang B, Matsuo K et al. Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer. Nat Genet. 45(2), 191-196 (2013).
49. Wang HM, Chang TH, Lin FM et al. A new method for post genome-wide association study (GWAS) analysis of colorectal cancer in Taiwan. Gene 518(1), 107-113 (2013).
50. Chen W, Xiang J, Chen DF et al. Screening for differentially methylated genes among human colorectal cancer tissues and normal mucosa by microarray chip. Mol. Biol. Rep. 40(5), 3457-3464 (2013).
51. Kim YH, Lee HC, Kim SY et al. Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann. Surg. Oncol. 18(8), 2338-2347 (2011).
52. Schuebel KE, Chen W, Cope L et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 3(9), 1709-1723 (2007).
53. Mori Y, Cai K, Cheng Y et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 131(3), 797-808 (2006).
54. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407), 330-337 (2012).
55. Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. Exp. Biol. Med. (Maywood) 229(10), 988-995 (2004).
56. Delgado-Plasencia L, Medina-Arana V, Bravo- Gutiérrez A et al. Impact of the MTHFR C677T polymorphism on colorectal cancer in a population with low genetic variability. Int. J. Colorectal. Dis. 28(9), 1187-1193 (2013).
57. Kibriya MG, Raza M, Jasmine F et al. A genome-wide DNA methylation study in colorectal carcinoma. BMC Med. Genomics 4, 50 (2011).
58. van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51(6), 797-802 (2002).
59. Beggs AD, Jones A, El-Bahwary M, Abulafi M, Hodgson SV, Tomlinson IP. Whole-genome methylation analysis of benign and malignant colorectal tumours. J. Pathol. 229(5), 697-704 (2013).
60. Ju HX, An B, Okamoto Y et al. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am. J. Pathol. 178(4), 1835-1846 (2011).
61. Yi JM, Dhir M, Van Neste L et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin. Cancer Res. 17(6), 1535-1545 (2011).
62. Kim JC, Lee HC, Cho DH et al. Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers. J. Cancer Res. Clin. Oncol. 137(10), 1571-1580 (2011).
63. Chen B, Dodge ME, Tang W et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5(2), 100-107 (2009).
64. Sack U, Walther W, Scudiero D et al. S100A4- induced cell motility and metastasis is restricted by the Wnt/b-catenin pathway inhibitor calcimycin in colon cancer cells. Mol. Biol. Cell 22(18), 3344-3354 (2011).
65. Hinoue T, Weisenberger DJ, Lange CP et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22(2), 271-282 (2012).
66. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38(7), 787-793 (2006).
67. Shen L, Toyota M, Kondo Y et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl Acad. Sci. USA 104(47), 18654-18659 (2007).
68. Yagi K, Akagi K, Hayashi H et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin. Cancer Res. 16(1), 21-33 (2010).
69. Nosho K, Irahara N, Shima K et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 3(11), e3698 (2008).
70. Patai AV, Molnár B, Tulassay Z, Sipos F. Serrated pathway: alternative route to colorectal cancer. World J. Gastroenterol. 19(5), 607-615 (2013).
71. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J. Mol. Diagn. 8(5), 582- 588 (2006).
72. Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 7, 72 (2007).
73. Goel A, Nagasaka T, Arnold CN et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132(1), 127-138 (2007).
74. Barault L, Charon-Barra C, Jooste V et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 68(20), 8541-8546 (2008).
75. Dahlin AM, Palmqvist R, Henriksson ML et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin. Cancer Res. 16(6), 1845-1855 (2010).
76. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 455(6), 485-494 (2009).
77. Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J. Pathol. 225(3), 336-343 (2011).
78. Yagi K, Akagi K, Hayashi H et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin. Cancer Res. 16(1), 21-33 (2010).
79. Ang PW, Loh M, Liem N et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer 10, 227 (2010).
80. Yamauchi M, Morikawa T, Kuchiba A et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61(6), 847-854 (2012).
81. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett. 268(2), 177-186 (2008).
82. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357(9255), 539-545 (2001).
83. Olaru AV, Cheng Y, Agarwal R et al. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers. Inflamm. Bowel Dis. 18(4), 641-648 (2012).
84. Patai AV, Molnár B, Kalmár A, Schöller A, Tóth K, Tulassay Z. Role of DNA methylation in colorectal carcinogenesis. Dig. Dis. 30(3), 310-315 (2012).
85. Tang D, Liu J, Wang DR, Yu HF, Li YK, Zhang JQ. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin. Invest. Med. 34(2), e88-e95 (2011).
86. Lange CP, Campan M, Hinoue T et al. Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS One 7(11), e50266 (2012).
87. Tóth K, Sipos F, Kalmár A et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One 7(9), e46000 (2012).
88. Bennett KL, Karpenko M, Lin MT et al. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res. 68(12), 4494-4499 (2008).
89. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61(3), 900-902 (2001).
90. Leung WK, To KF, Man EP et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am. J. Gastroenterol. 100(10), 2274-2279 (2005).
91. Nakayama H, Hibi K, Takase T et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int. J. Camcer 105(4), 491-493 (2003).
92. Zou HZ, Yu BM, Wang ZW et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. 8(1), 188-191 (2002).
93. Muller HM, Widschwendter M. Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev. Mol. Diagn. 3(4), 443-458 (2003).
94. deVos T, Tetzner R, Model F et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 55(7), 1337-1346 (2009).
95. Lofton-Day C, Model F, Devos T et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54(2), 414-423 (2008).
96. Wallner M, Herbst A, Behrens A et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin. Cancer Res. 12(24), 7347-7352 (2006).
97. Herbst A, Wallner M, Rahmig K et al. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur. J. Gastroenterol. Hepatol. 21(5), 565-569 (2009).
98. Tang D, Liu J, Wang DR, Yu HF, Li YK, Zhang JQ. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin. Invest. Med. 34(2), e88-e95 (2011).
99. Herbst A, Rahmig K, Stieber P et al. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am. J. Gastroenterol. 106(6), 1110-1118 (2011).
100. Ahlquist DA, Taylor WR, Mahoney DW et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin. Gastroenterol. Hepatol. 10(3), 272-277 (2012).
101. Tanzer M, Balluff B, Distler J et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 5(2), e9061 (2010).
102. Li M, Chen WD, Papadopoulos N et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 27(9), 858-863 (2009).
103. Kim TO, Park J, Kang MJ et al. DNA hypermethylation of a selective gene panel as a risk marker for colon cancer in patients with ulcerative colitis. Int. J. Mol. Med. 31(5), 1255-1261 (2013).
104. Balasubramanyam K, Varier RA, Altaf M et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase- dependent chromatin transcription. J. Biol. Chem. 279(49), 51163-51171 (2004).
105. Liu Z, Xie Z, Jones W et al. Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett. 19(3), 706-709 (2009).
106. Link A, Balaguer F, Shen Y et al. Curcumin modulates DNA methylation in colorectal cancer cells. PLoS One 8(2), e57709 (2013).